Ambio ibogaine program treats Parkinson’s
A new clinical program will use ibogaine, a naturally occurring psychedelic to treat neurodegenerative conditions including Parkinson’s di...
https://www.thrivingwithparkinsons.com/2025/06/a-new-clinical-program-will-use.html
A new clinical program will use ibogaine, a naturally occurring psychedelic to treat neurodegenerative conditions including Parkinson’s disease.
Life Sciences, which hosts other ibogaine programming and participates in scientific research about the drug, soft-launched the program in February. It is the first of its kind in the world, according to the company. People with Parkinson’s, multiple sclerosis (MS), and traumatic brain injury (TBI) may be eligible.
